Abstract Number: 700 • 2014 ACR/ARHP Annual Meeting
Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease
Background/Purpose In a previous study, performed 9±3.6 years ago 74 asymptomatic patients with systemic lupus erythematosus (SLE) and or antiphospholipid syndrome (APS) who fulfilled the…Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling - sifalimumab or anifrolumab, specific for IFN-α…Abstract Number: 718 • 2014 ACR/ARHP Annual Meeting
Safety of Gardasil® Vaccine in Systemic Lupus Erythematosu, Trial Update
Background/Purpose: Cervical neoplasia is increased in women with SLE presumably due to cervical infection with oncogenic Human Papillomavirus (HPV) types which persist in an immunosuppressed…Abstract Number: 717 • 2014 ACR/ARHP Annual Meeting
Comparison of Responsiveness of Lupus Impact Tracker with Lupus Quality of Life to Selena Responder Index
Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…Abstract Number: 716 • 2014 ACR/ARHP Annual Meeting
Simple Disease Assessment for People with Lupus Erythematosus
Background/Purpose: Community rheumatologists treating patients with Systemic Lupus Erythematosus (SLE) typically lack user-friendly tools to effectively track SLE disease activity. Current disease activity tools in…Abstract Number: 715 • 2014 ACR/ARHP Annual Meeting
The REAL Life with Lupus Study: Developing a Patient Reported Outcome Measure for Use in Clinical Trials and Clinical Care
Background/Purpose: The goal of this study is to better understand how people with systemic lupus erythematosus (SLE) in the United States experience the disease. Results…Abstract Number: 714 • 2014 ACR/ARHP Annual Meeting
The Validity of Patient and Physician Global Disease Activity Assessments of Systemic Lupus Erythematosus: Results from the Lupus Activity Scoring Tool (LAST) As Compared to the Selena Sledai (SS) Modification Multicentre Study
Background/Purpose In our centre, new tools for the assessment of SLE activity: the Lupus Activity Scoring Tool (LAST) and Clinical Lupus Activity Scoring Tool (C-LAST)…Abstract Number: 713 • 2014 ACR/ARHP Annual Meeting
Lupuspro Is Responsive to Changes in Disease Activity over Time
Background/Purpose: Patient reported outcome (PRO) tools are important to understand, educate, manage, and follow patients with systemic lupus erythematosus (SLE). Disease targeted PRO for SLE…Abstract Number: 712 • 2014 ACR/ARHP Annual Meeting
Mapping the Disease-Specific Lupusqol to the SF-6D
Background/Purpose: The LupusQoL is a measure of health-related quality of life (HRQoL) developed specifically to assess the impact of systemic lupus erythematosus (SLE) and its…Abstract Number: 711 • 2014 ACR/ARHP Annual Meeting
Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare?
Background/Purpose With improving survival in SLE patients, patient-reported health-related quality of life (HRQoL) has become an important outcome. The LupusQoL is a disease-specific patient-derived HRQoL measure…Abstract Number: 710 • 2014 ACR/ARHP Annual Meeting
Splenectomy in Systemic LUPUS Erythematosus and AUTOIMMUNE Hematological Diseases. a Comparative Analysis
Background/Purpose Acute presentation of severe autoinmune thrombocytopenia, and hemolytic anemia in systemic lupus erythematosus (SLE) is associated with high mortality. Splenectomy is the second line…Abstract Number: 709 • 2014 ACR/ARHP Annual Meeting
Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (PSQI)in Female with Systemic Lupus Ertyhematosus (SLE).
Background/Purpose Despite the fact that sleep disorders are poorly studied, they´re a frequent complain by patients with SLE (62 to 80% related) and others found…Abstract Number: 708 • 2014 ACR/ARHP Annual Meeting
Determining Risk Factors That Increase Hospitalizations in Patients with Systemic Lupus Erythematosis
Background/Purpose Systemic lupus erythematosis (SLE) is a complex heterogeneous disease which can be associated with significant morbidity and mortality. Hospitalization and readmissions have garnered significant…Abstract Number: 707 • 2014 ACR/ARHP Annual Meeting
Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody
Background/Purpose Pulmonary involvement is frequent in systemic lupus erythematosus (SLE) and can affect the pleura, pulmonary vasculature, and parenchyma. The prevalence of ILD is lower…Abstract Number: 681 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated Independently with Improved Quality of Life in Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) has been shown to be beneficial to patients with Systemic Lupus Erythematosus (SLE), however, its effects on the quality of life (QOL)…
ACR Meeting Abstracts